MXPA98009764A - Improvements in, or related to, compositions containing creat - Google Patents
Improvements in, or related to, compositions containing creatInfo
- Publication number
- MXPA98009764A MXPA98009764A MXPA/A/1998/009764A MX9809764A MXPA98009764A MX PA98009764 A MXPA98009764 A MX PA98009764A MX 9809764 A MX9809764 A MX 9809764A MX PA98009764 A MXPA98009764 A MX PA98009764A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- creatine
- composition according
- beverage
- isotonic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 240000002556 Andrographis paniculata Species 0.000 title 1
- 229960003624 Creatine Drugs 0.000 claims abstract description 92
- 239000006046 creatine Substances 0.000 claims abstract description 92
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine zwitterion Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 91
- 235000013361 beverage Nutrition 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 17
- 239000002253 acid Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 235000013618 yogurt Nutrition 0.000 claims description 19
- 239000003792 electrolyte Substances 0.000 claims description 11
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 230000002378 acidificating Effects 0.000 claims description 8
- 229940076788 Pyruvate Drugs 0.000 claims description 7
- LCTONWCANYUPML-UHFFFAOYSA-M pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- 229940029983 VITAMINS Drugs 0.000 claims description 5
- 229940021016 Vitamin IV solution additives Drugs 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 239000011575 calcium Chemical class 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- 239000011777 magnesium Chemical class 0.000 claims description 5
- 229910052749 magnesium Chemical class 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229930003231 vitamins Natural products 0.000 claims description 5
- RXKJFZQQPQGTFL-UHFFFAOYSA-N Dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims description 4
- 229940120503 Dihydroxyacetone Drugs 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 239000011591 potassium Chemical class 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000008122 artificial sweetener Substances 0.000 claims description 3
- 235000021311 artificial sweeteners Nutrition 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000000111 anti-oxidant Effects 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 230000002335 preservative Effects 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 235000021057 semi-liquid food Nutrition 0.000 claims description 2
- 239000011573 trace mineral Substances 0.000 claims description 2
- 235000013619 trace mineral Nutrition 0.000 claims description 2
- 239000006096 absorbing agent Substances 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 238000003860 storage Methods 0.000 abstract description 11
- 239000000243 solution Substances 0.000 description 22
- 229940109239 Creatinine Drugs 0.000 description 15
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 15
- 238000009472 formulation Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 5
- 229960003438 Aspartame Drugs 0.000 description 5
- 108010011485 Aspartame Proteins 0.000 description 5
- 239000000605 aspartame Substances 0.000 description 5
- 235000010357 aspartame Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 210000001124 Body Fluids Anatomy 0.000 description 4
- 229940077731 Carbohydrate nutrients Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000001502 supplementation Effects 0.000 description 4
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 3
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 description 3
- 241000207199 Citrus Species 0.000 description 3
- 229960004826 Creatine Monohydrate Drugs 0.000 description 3
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 3
- 235000020971 citrus fruits Nutrition 0.000 description 3
- 229960000673 dextrose monohydrate Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000036545 exercise Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 229960002747 Betacarotene Drugs 0.000 description 2
- 240000002268 Citrus limon Species 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 2
- 229940064302 Folacin Drugs 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 235000021102 Greek yogurt Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- 229940053207 Niacin Drugs 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N Phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 229960002477 Riboflavin Drugs 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- AUNGANRZJHBGPY-OUCADQQQSA-N Riboflavin Natural products OC[C@@H](O)[C@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-OUCADQQQSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 229940011671 Vitamin B6 Drugs 0.000 description 2
- 229930003629 Vitamin B6 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229940046009 Vitamin E Drugs 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- OENHQHLEOONYIE-VYAWBVGESA-N beta-Carotene Natural products CC=1CCCC(C)(C)C=1\C=C\C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-VYAWBVGESA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 125000003346 cobalamin group Chemical group 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 230000003204 osmotic Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 230000004078 physical exercise Effects 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003700 vitamin C derivatives Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003712 vitamin E derivatives Chemical class 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 208000004981 Coronary Disease Diseases 0.000 description 1
- 240000002275 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 229940109275 Cyclamate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229960001031 Glucose Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 229940077676 Low-energy diet formulations for treatment of obesity Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L Magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 210000003254 Palate Anatomy 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 229940055726 Pantothenic Acid Drugs 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Sodium cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- DAEPDZWVDSPTHF-UHFFFAOYSA-M Sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 210000004243 Sweat Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 235000019742 Vitamins premix Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- -1 acesulfan K Chemical compound 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- UZWMCCLZMHPPKW-UHFFFAOYSA-L calcium;2-oxopropanoate Chemical compound [Ca+2].CC(=O)C([O-])=O.CC(=O)C([O-])=O UZWMCCLZMHPPKW-UHFFFAOYSA-L 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 201000008739 coronary artery disease Diseases 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002270 ergogenic Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000009754 grape Nutrition 0.000 description 1
- 235000012333 grape Nutrition 0.000 description 1
- 238000011141 high resolution liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 239000011776 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 235000020825 overweight Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N pantothenic acid Natural products OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- JKVUQLWTIZFTMF-UHFFFAOYSA-M potassium;2-oxopropanoate Chemical compound [K+].CC(=O)C([O-])=O JKVUQLWTIZFTMF-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
The present invention relates to an acid composition for human consumption, comprising creatine. In particular, the composition is conveniently an isotonic beverage for storage at 4 ° C, or it is a stable powder that can be stored at room temperature.
Description
IMPROVEMENTS IN PTCT.af EQNADAS WITH COMPOSITIONS CONTAINING CREATIN
FIELD OF THE INVENTION
This invention relates to compositions for human consumption comprising creatine, and to a method for providing stable compositions containing creatine.
ANTECEDENTS OF THE TJNVENTION
Governments are currently concerned with the high incidence of obesity (and less degrees of weight gain) in populations, since it represents a known risk factor for coronary heart disease, hypertension and diabetes. In addition to diet modification, the main thought of treatment and weight maintenance after weight loss is physical exercise. Now it is suggested by experts that the diet itself is insufficient in the long term to maintain weight loss without altering the lifestyle, in particular to perform more exercise. However, one of the problems experienced by overweight people is that they find physical activity tired and fatigued easily. There is a need for a regimen which makes obese people fatigue less so that they can exercise for longer periods, burn more calories and lose more weight, or maintain their weight better after losing weight. In addition, in recent years there has been considerable interest among athletes in creatine, which occurs abundantly in skeletal muscle. Creatine plays a basic role in the regulation and homeostasis of skeletal muscle energy metabolism and it is now generally accepted that the maintenance of phosphocreatine availability is important for the continuation of muscle force production. Although creatine synthesis occurs in the liver, kidney and pancreas, it has been known for some time that oral ingestion of creatine can help the total body pool of creatine, and it has been shown that ingestion of 20 to 30 g of creatine per day for several days can lead to a greater than 20% increase in the total creatine content in human skeletal muscle. Therefore, document O94 / 02127 describes the administration of creatine in amounts of at least 15 g (or 0.2-0.4 g / kg body weight) per day, for at least 2 days, to increase muscular endurance. In fact, it was later found that, after several days of supplementation (20 g per day) with creatine, no more than 2 or 3 g per day are required to maintain the saturation of the body stores. Supplementation with creatine in an appropriate dose can provide improvement to athletes involved in high-wear events which include all events that last from a few seconds to a few minutes (such as start of race, swimming, weight lifting, etc.). Resistance in events that last more than about 30 minutes seems not to be affected with the creatine supplement. Creatine is a normal food component and is not a drug and its use is not contrary to official regulations. The greatest benefits of supplementation can be experienced by vegetarians or those who do not eat meat or fish, since these people tend to have a low content of muscle creatine. During the last years there has been considerable interest in the use of isotonic drinks that yield to physical exercise. Human body fluids comprise water and substances dissolved therein, such as mineral salts known as electrolytes. These allow electrical impulses to stimulate muscular action. Isotonic drinks replace essential electrolytes lost in sweat during and / or after exercise. The term isotonic is applied to beverages that contain the same concentration of minerals as body fluids and in which the osmotic pressure is the same as that exerted by human body media. The most important electrolytes used in isotonic drinks are sodium, chloride, potassium, calcium, magnesium and phosphorus. The isotonic drinks can be made already diluted with water or they can be conveniently packed in sacks or cans as a powder which must be subsequently mixed with non-foamy or carbonated water to provide a refreshing-tasting drink, for example of citrus flavor. It is well known that creatine is unstable in aqueous solutions at acidic or neutral pH, and becomes a related compound, creatinine. It is highly significant that creatinine does not have an improving effect on muscle function and is excreted from the human body as a waste product in urine. In view of the foregoing, EP 0 669 083 discloses that aqueous beverages for human consumption that comprise creatine should be weakly alkaline, in order to avoid the conversion of creatine into creatinine, and this has become the generally accepted opinion.
BRIEF DESCRIPTION OF THE INVENTION
In a first aspect, the invention provides an acid composition for human consumption, comprising creatine. The term "acid" is intended to mean that the composition has a pH less than 7.0. In particular, the composition desirably has a pH between 2.5 and 6.5, preferably between 3.0 and 6.0. Typically, the composition has a pH in the range of 3.5 to 5.5 which, for the human palate, has a strong refreshing flavor without being too acidic.
The creatine content of the composition may be present as any active form of creatine (eg, creatine phosphate) but creatine monohydrate is found to be particularly convenient as a source of creatine. The composition may be in the form of a dry powder or may be provided in liquid or semi-liquid form (for example as a beverage or yogurt, respectively). In preferred embodiments, the composition is a beverage which is isotonic (ie, corresponds to the osmotic potential of human body fluids) and / or comprises electrolytes. Conveniently, the composition will be constituted of electrolytes and will be isotonic. The present inventors have found that the conversion of creatine to creatinine to acidic pH is actually low enough to allow physiologically useful amounts of creatine to remain in the composition after considerable periods of time, so that creatine may be present in formulations acids, contrary to the teaching of the technique. In particular, the conversion of creatine to creatinine can be greatly inhibited by storage (for example in commercial refrigerant cabinets at 4-8 ° C) of the composition at lower temperatures than in the environment. Therefore, in a second aspect, the invention provides a method for storing a liquid or semi-liquid, acidic composition comprising creatine for human consumption, the method comprising storing the composition below room temperature, typically in a commercial refrigerating cabinet. at 4-8 ° C of the conventional family class for any medium or large sized retailer. Typically, the composition is an aqueous (preferably isotonic) drink or a yogurt or similar semi-liquid food. The beverage may be non-frothy or carbonated, and preferably comprises a citrus flavor. Alternatively, the composition can be provided as a dry powder which, when mixed with (preferably dissolves in) a predetermined volume of liquid (for example of substantially neutral pH) gives rise to an acid solution. The creatine content of the composition is stable as a dry powder at room temperature. The appropriate doses of the powder can then be dissolved as required, to form fresh beverages with substantially no decrease in creatine content. The powder can be dissolved in any suitable liquid (for example water, milk) or a semiliquid (for example yogurt). Accordingly, in a further aspect, the invention provides a method for delivering a composition containing creatine for human consumption, the method comprising providing an acidic composition containing creatine as a stable, dry powder, which, when mixed with water or a suitable aqueous solution produces an acid beverage comprising physiologically effective amounts of creatine. Typically, the powder is such that, when a certain amount is dissolved in a predetermined volume of water, it provides an isotonic beverage. Desirably, the powder is provided as unit doses (of about 10-20 grams) which can be dissolved in 200-350 ml of water to provide an isotonic beverage. The unit doses are conveniently supplied individually packaged in pouches, bags, packages, cylinders, bottles or other suitable packaging means. Preferably, the package is hermetically sealed (for example, a thin sheet pouch) to prevent the ingress of water or steam. Sometimes it may be desirable to provide a volumetric measuring means with the package to allow the user to measure an appropriate volume of water in which to dissolve the contents of the package. Typically, this may take the form of a water-tight container (eg, of plastic material) with one or more graduations to indicate a certain volume. The container may take the form of a pitcher with a spout or similar container, to retain water in which the composition is to be dissolved, and from which the resulting solution may be ingested. Preferably, the composition will consist of one or more additional components to improve its palatability, stability, flavor or nutritional quality. These additional components may include electrolytes, as already mentioned above, or may be selected from the group consisting of: vitamins, lipids, carbohydrates, amino acids, trace elements, colorants, flavors, artificial sweeteners, antioxidants, stabilizers, preservatives and buffers . People on diets to lose weight often receive a reduced intake of vitamins, so that these should be included with advantage in the composition of the invention. The following vitamins can be added in amounts ranging from 20 to 100% of the recommended daily requirements (RDA). The following are typical of those which are useful: vitamin E, vitamin C, thiamine, riboflavin, niacin, vitamin B6, folacin, vitamin B12, biotin and pantothenic acid. In some cases, a lipid component may be desirable. The carbohydrate component (if any) of the composition can be present as starch (particularly soluble starch) and / or sugars. The carbohydrates used in the invention can preferably be used in amounts which are consistent with the isotonicity of the composition in its preferred embodiments, taking into consideration the effect of the creatine content. The osmolarity of the beverage should preferably not exceed 320 mOsm + or - 10%. The sugars which may be present in the composition include glucose, fructose, sucrose and maltose.
Artificial sweeteners which may be used include aspartame, acesulfan K, saccharin and cyclamate. Almost any desired flavoring can be added, more preferably citrus flavors such as lemon, orange and grapefruit. Citric acid can also be used as an acidulant and as a buffering agent. Colorants can be provided, typically by the use of a cold water soluble dye such as beta carotene. Other suitable coloring substances will be apparent to those familiar with the art. A clouding agent may be included in the composition to improve the appearance of the finished beverage and differentiate it from a lemonade. You can add minerals of any type or shape which provide in combination, the correct osmolarity and / or containing electrolytes in quantities which approximate the composition with body fluids. It is convenient to provide calcium and potassium in the form of its phosphates or acid phosphates, and magnesium as the oxide or carbonate. Typically, the amounts are: sodium at 400 mg / liter, calcium at 100 mg / liter, chloride at 600 mg / liter, potassium at 200 mg / liter, magnesium at 75 mg / liter and phosphorus at 50 mg / liter. The amount of creatine per liter of beverage prepared can vary from 0.5 to 30 g, with a preferred content of approximately 12 g per liter. The normal portion size is in the range of 250-330 ml, which provides approximately 3 g of creatine. During the first 4 days of creatine supplementation, the recommended intake is 1.5 liters per day divided into 4 to 5 parts per day to obtain creatine saturation. This is followed by a drink of 250 ml per day containing 3 g of creatine to provide a maintenance concentration of creatine. In some embodiments, the composition may additionally be comprised of pyruvate and / or dihydroxyacetone. Pyruvate and dihydroxyacetone are ergogenic compounds present in the body and have been shown to improve submaximal resistance (RT Stanko et al., 1993 Sports Sciences 11, 17-23) and when substituted by carbohydrates in the diet they are useful for increasing weight loss in low energy diets (RT Stanko et al., 1992, Am. J. Clin. Nutr 56, 630-5). Pyruvate can be provided as a salt, preferably the sodium, potassium, magnesium or calcium salt. Pyruvate can be used without dihydroxyacetone or as a mixture with it, for example, as a 1: 3 mixture (P: DHA). The total amount of pyruvate and / or DHA per 250 ml portion of the composition may be in the range of 1 to 25 g, conveniently 5-15 g. The invention will now be further described by way of illustrative example and with reference to the accompanying drawings in which: Figures 1 and 2 are graphs of creatine concentration against time; and Figures 3-6 are graphs of creatine% versus time.
EXAMPLES
Example 1
These examples describe the detailed formulation of an acid composition according to the invention. The composition takes the form of a dry powder, which must be dissolved in water to constitute the isotonic drink comprising creatine.
Ingredients Dextrose monohydrate 300 g Citric acid 32 g Pectin (stabilizer) 6.0 g Salt 5.0 Trisodium citrate 5.0 Beta carotene 3.0 Potassium chloride 2.9 Melon grape flavor 2.9 Tricalcium phosphate 2.1 g Heavy magnesium carbonate 2.1 g Vitamin premix 1.8 g Lemon flavor 1.4 g Orange flavor 1.4 g Aspartame 1.0 g Creatine monohydrate 88 g
When 63 g of the above mixture are dissolved in 1 liter of water, approximately 3 g of creatine, 203 kg of energy (48 kcal), 11.1 g of carbohydrates, 156 mg of chloride, 100 mg are provided per 250 ml portion. sodium, 52 mg of potassium, 26 mg of calcium, 19.5 mg of magnesium, 13 mg of phosphorus, vitamins (3.4 mg of vitamin E, 16.2 mg of vitamin C, 0.3 mg of thiamin, 0.4 mg of riboflavin, 5.0 mg of niacin, 0.4 mg of vitamin B6, 85 μg of folacin, 0.9 μg of vitamin B12, 0.08 mg of biotin and 2.2 mg of pathogenic acid) and traces of protein, fats and fiber. This provides a refreshing isotonic beverage containing electrolytes and creatine which is relatively lower in calories compared to conventional isotonic drinks and has a pH of about 3.8.
This example relates to another embodiment of the invention. The formulation is as in Example 1 above, except that 300 g of dextrose monohydrate is suppressed and the content of aspartame is increased to 2.5 g to compensate. When 5.3 g of this formulation dissolves in 250 ml of water, an almost calorie-free beverage containing creatine and electrolytes is provided which, while not isotonic, is nutritionally useful for those who wish to lose or maintain their weight.
Example 3
This example relates to another embodiment of the invention. The formulation is as in Example 1 above, except that half of dextrose monohydrate is abolished and replaced by the same weight of sodium, calcium or potassium pyruvate, together with the addition of 0.75 g of aspartame (which provides an amount total of 1.75 grams of aspartame). A typical portion of this formulation is 15.75 g mixed in 250 ml of water.
Example 4 This example relates to a study of the stability of creatine under sterile conditions at pH over a period of two weeks. A dry powder composition according to the invention is prepared and stored in 14 gram samples. The composition is essentially as described in example 1. Each sample of 14 g of the composition consists of approximately 3 g of creatine. 14 g of the powder composition are dissolved in 400 ml of distilled water, and the solution is incubated under sterile conditions at 25-26 ° C for 2 weeks. The pH of the composition at the beginning of the experiment is 3.66. 5 ml aliquots are removed aseptically from the solution during the course of the experiment and analyzed to determine the creatine and creatinine concentration. These determinations were carried out simultaneously by reversed phase ionic phase high resolution liquid chromatography, according to the method of Murakita (1988 J. or Chromatography 432, 471-473). The experiment is carried out in triplicate and the results are shown below in table 1.
Table 1
These results are also represented graphically in figures 1-3. Figure 1 is a graph of an average concentration of creatine (black circles) or the concentration of creatinine (white circles) in mmoles / liter, against time (measured in hours, days or weeks). Figure 2 is a similar graph showing the creatine or creatinine mean of the composition, in grams / 400 ml, against time. Figure 3 is a graph showing the percentage of unconverted creatine (black circles) or the percentage of creatine converted to creatinine (white circles) against time. From these data, it is evident that acidic creatine solutions can be stored at room temperature for 24 hours with very little loss of creatine. Longer storage (for 2-3 days) is possible without a serious loss of creatine).
Example 5
This example is related to a study of creatine stability for 3 days in aqueous solutions at different pH values. 42 grams (three samples of 14 g) of the powder formulation described in the preceding example are dissolved, in 750 ml of distilled water heated to 25 ° C, seven aliquots of 100 ml (called AG, respectively) are extracted into beakers. precipitates of polystyrene of known weight and are reweighed. The pH of the aliquots is adjusted to the desired values (A = pH 2.5, B = 3.5, C = 4.5, D = 5.5, E = 6.5, F = 7.5, G = 8.5) using 50% acetic acid or 5N KOH . After adjusting the pH, the beakers are reweighed to ensure that the increase in volume is less than 5% (i.e., less than 5 ml). The samples are kept at 25 ° C for 24 hours and 5 ml aliquots are extracted for creatine and creatinine concentration analysis, (as previously described) at the time points of 0.5 h, 4 h, 8 h, 1 day and 3 days. The pH of the solutions was also tested, to ensure that the pH is not greatly altered during the development of the experiment. These results are shown in table 2 below.
Table 2
With reference to figure 4, the figure shows a graph of% creatine that remains against time (measured in hours or days) for the A-F solutions. The results for solutions A (pH 2.5) and G (pH 8.5) are omitted for clarity. The legend is as follows: black squares = solution B (pH 3.5), white squares - solution C (pH 4.5), white triangles = solution D (pH 5.5), black triangles = solution E (pH 6.5) and white circles = solution F (pH 7.5). It can be seen that, in general, the lower the pH the faster is the conversion of creatine to creatinine, but even in solutions of pH 4.5 or similar, they are reasonably stable for up to 3 days. The decomposition after 3 days at pH 5.5, 4.5 and 3.5 is 4%, 12% and 21%, respectively. In fact, it has been found that an exception to this general rule is that creatine is more stable at pH 2.5 than at pH 3.5. After 3 days, the decomposition at pH 2.5 is found to be "13%, similar to that which occurs at pH 4.5.
Example $
This example is related to a study of creatine stability over a period of 52 days in aqueous solutions at different pH values that are maintained at a lower temperature than the environment (specifically, 4 ° C). First, because creatine has poor solubility in water at 4 ° C, an experiment is performed to ensure that the creatine concentrations used in the determination of stability do not lead to creatine precipitation for a period of 5 weeks. The determination of solubility was carried out as follows: 1.2 g of creatine monohydrate are dissolved in 100 ml of buffer solutions (prepared by mixing 200 mM K2HP04 and 200 mM acetic acid, and adjusting the pH by the addition of 5M KOH) apH 3.5 , pH 5.0, pH 6.0 and pH 7.0 at room temperature.
The dilutions were made with distilled water for each pH value: A) without dilution B) - 9: 1 (buffer: water) C) - 8: 2"D) - 7: 3" E) - 6: 4 F) - 5: 5"
The final solutions were stored in capped plastic tubes. The tubes are stored at 4 ° C, shaken every 2 hours or similar and the time of occurrence of precipitation is noted. The relative amount of precipitation is recorded after storage for 78 hours at 4 ° C and the results are presented below in Table 3. Tube D (7: 3 dilution) has the highest concentration of creatine which does not show precipitation after 78 hours. The concentration of creatine in tube D is 8.4 g / 1. Accordingly, the stability determination experiments were performed using the same initial concentration of creatine.
Table 3
Relative precipitation: *** = heavy; ** = moderate; * = light; = none
The determination of stability was made as follows.
14 g of the formulations described in Example 4 are dissolved in 250 ml of distilled water. Additionally, 14 g of a second formulation is dissolved in 500 ml. The second formulation does not contain any creatine, but otherwise it is identical to the formulation described in example 4. 107 ml of a second solution is added to the first solution, resulting in a 7: 3 dilution. Four aliquots of 60 ml are removed and the pH adjusted with 5M KOH to: A - unadjusted pH; B - pH 5.0; C - pH 6.0; D - pH 7.0. Aliquots of 40 ml are extracted for storage in plastic tubes at 4 ° C. Samples of 0.5 ml of AD are extracted and diluted directly in 100 ml of distilled water at 0 h, 2 d, 7 d, 14 d, 28 d, 35 d and 52 d for creatine and creatinine analysis by CLAP, as describes previously. The pH of the samples is also determined to ensure that it has not changed during the course of the experiment. The results are shown below .
Table 4 pH of the samples over the course of the experiment
The results of the creatine stability analysis are shown below in table 5.
Table 5 - Creatine stability during 52 days of storage at 4 ° C.
ÍCrl or fCnl in mmol / l day 0% of Cr remaining on the day [Cr] [Cn] 0 2 7 14 28 35 52
A 60.79 0.00 100 99.4 98.6 97.0 94.0 92.7 92.1 B 55.40 0.00 100 100 99.4 98.8 97.0 96.0 95.8
C 60.32 0.00 100 100 99.7 99.7 99.3 98.6 98.6
D 59.68 0.00 100 100 100 100 99. 99.6 99.4
The above results are also presented graphically in Figure 5. Figure 5 is a graph of creatine% that remains against time (in days). White circles with solid lines show results for solution A, black circles with dotted lines show results for solution B, white circles with a dashed line show results for solution C, and black circles with a line with points and ions shows the result for solution D. These data show that, even at a pH as low as 3.5-3.6 after storage for 5 weeks at 4 ° C, only 7.3% of the creatine had converted to creatinine, and there was very little change after day 52, indicating that an equilibrium has been reached that leaves significant amounts of creatine available for physiological benefit. Therefore, an acid formulation comprising creatine can be prepared and stored successfully especially with storage at temperatures below ambient.
Example 7
This example is related to a study of the stability of creatine during several weeks in different commercially available yogurts (acids), during storage at 4 ° C. The study was conducted as follows. 0.5 g of monohydrated creatine was mixed with 100 g of a commercially available yogurt to provide a creatine concentration of approximately 3.4 mmol per 100 g. The supplemented yogurt is placed in a common refrigerator set at 4 ° C. At various times, 2 g of the supplemented yogurt are taken and placed in 100 ml of distilled water. Filter 1 ml of the resulting solution using a Whatman microfilter with 12 kilodalton pore size, and the clear filtrate is tested to determine creatine and creatinine concentrations as previously described. Three different types of yogurt (purchased from Tesco's stores) were used in the experiment: a low-fat natural yogurt, a "healthy eating bio" yogurt, "healthy eating bio" and a Fage Greek yogurt, the results of the creatine analysis were shown below in table 6, and are graphically depicted in figure 6. Figure 6 shows a plot of% creatine remanent against time (in days) The tables show the results for low fat yogurt, the circles show the results for the "healthy eating" yogurt and the triangles show the results for the Greek yogurt The creatine stability in the different yoghurts is remarkably similar The amount of conversion of creatine to creatinine is about 6% or less after 31 days of storage at 4 ° C.
Table 6 - Creatine stability in three different commercially available yogurts
The presence of live bacteria in yogurt does not seem to have any harmful effect. Therefore, yogurt represents an extremely useful vehicle for a composition containing creatine, especially as yogurt that are conventionally handled and stored at temperatures below the ambient - the presence of creatine in the yogurt does not need any additional handling requirement in relation to at storage temperature.
Claims (15)
1. An acid composition for human consumption, characterized in that it comprises creatine and one or more additional components that are selected from the group consisting of: vitamins, lipids, carbohydrates, amino acids, trace elements, colorants, flavors, artificial sweeteners, antioxidants, stabilizers, preservatives and shock absorbers.
2. The composition according to claim 1, characterized in that the composition is a coil which is isotonic and / or comprises electrolytes.
3. The composition according to claim 1 or 2, characterized in that the composition is an isotonic beverage comprising electrolytes.
4. The composition according to any of claims 1-3, characterized in that it has a pH in the range of 2.5-6.5.
5. The composition according to any of the preceding claims, characterized in that it has a pH in the range of 3.0 to 6.0.
6. The composition according to any of the preceding claims, characterized in that it comprises pyruvate and / or dihydroxyacetone.
7. The composition according to any of the preceding claims, characterized in that it comprises pyruvate as the salt or salts of sodium, potassium, calcium or magnesium thereof.
8. The composition according to claim 1, characterized in that the composition is a dry, stable powder.
9. The composition according to claim 1, characterized in that when mixed with a predetermined volume of liquid, it produces a beverage according to any of claims 2 to 7.
10. The composition according to any of the preceding claims, characterized in that it is provided as a unit dose.
11. The composition according to claim 1, characterized in that the composition is a yogurt or other semiliquid food.
12. A method for delivering a composition containing creatine for human consumption, the method is characterized in that it comprises providing an acidic composition containing creatine as a stable, dry powder which, when mixed with water or a suitable aqueous solution, provides an acidic beverage. comprising physiologically effective amounts of creatine.
13. The method according to claim 12, characterized in that the powder is provided in unit doses which, when mixed with a predetermined volume of water, produce an isotonic beverage.
14. A method for storing a liquid or semi-liquid composition for human consumption, comprising creatine, the method is characterized in that it comprises storing the composition below room temperature.
15. The method according to claim 14, characterized in that the composition is stored at 4-8 ° C.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9611356.8 | 1996-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA98009764A true MXPA98009764A (en) | 1999-09-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5968544A (en) | Compositions containing creatine | |
US6039987A (en) | Physical endurance drink and method of preventing cramping caused by strenuous bodily activity | |
US7150880B2 (en) | Compositions containing creatine and creatinine and a methyl xanthine | |
US5032411A (en) | Beverage compositions for human consumption | |
US5114723A (en) | Beverage compositions for human consumption | |
US6835402B1 (en) | Carbonated fortified milk-based beverage and method for suppressing bacterial formation in the beverage | |
US6274161B1 (en) | Compositions containing creatine in suspension | |
US20020132780A1 (en) | Low carbohydrate compositions, kits thereof, and methods of use | |
US20030069202A1 (en) | Compositions, kits, and methods for promoting defined health benefits | |
US20020187219A1 (en) | Low glycemic response compositions | |
JPH0234590B2 (en) | ||
JP2004500031A (en) | Compositions, kits and methods for providing and maintaining vitality and mental agility | |
US6524611B2 (en) | Compositions containing creatine and creatinine | |
US20020132034A1 (en) | Isotonic juice drink for children | |
US6168802B1 (en) | Compositions containing creatine and aloe vera extract | |
US5141758A (en) | Method for extending life of vitamin C in drink | |
WO1998032344A1 (en) | CALCIUM FORTIFIED LOW pH BEVERAGE | |
US20060246200A1 (en) | Hydroxyapatite in aqueous solution for bone health | |
CA2438622C (en) | Compositions containing creatine and creatinine | |
CA2408610A1 (en) | Low carbohydrate compositions, kits thereof, and methods of use | |
MXPA98009764A (en) | Improvements in, or related to, compositions containing creat | |
JP6714984B2 (en) | Container-packed acidic beverage with high citric acid content and reduced off-flavor derived from citric acid | |
Baker-Fulco et al. | SUPPLEMENTAL BEVERAGE FORMULATION |